Several Lots of Human Growth Hormone Have Been Recalled
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
Innoveix Pharmaceuticals, a compounding pharmacy in Addison, Tex., is voluntarily recalling several lots of compounded drug products. The products are being recalled due to a lack of assurance of sterility. The issues where discovered during a routine inspection by the FDA.
The affected products are injectable sermorelin/ipamorelin 3mg and injectable AOD-9604 3mg. Sermorelin and ipamorelin are human growth hormone secretagogues (GHSs), which are compounds that increase growth hormone release. AOD is a synthetic peptide thought to have potential for weight loss.
To date, Innoveix Pharmaceuticals has not received any reports of adverse events related to this recall.
Sermorelin / Ipamorelin 3mg
- Lot# SIP210; Exp: 12/15/2021
- Lot# SIP215; Exp: 01/14/2022
- Lot# SIP220; Exp: 01/23/2022
AOD-9604 3mg
- Lot# AOD205; Exp: 11/09/2021
- Lot# AOD210; Exp: 11/18/2021
- Lot# AOD 215; Exp: 12/15/2021
- Lot# AOD202; Exp: 11/09/2021
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
